NCT06590324View on ClinicalTrials.gov

A Study of Apabetalone in Subjects With Long -COVID

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

December 30, 2025

Study Completion Date

March 30, 2026

Conditions
Post-Acute COVID-19 Syndrome
Interventions
DRUG

Apabetalone

100-mg capsule, twice daily oral administration with meals

Trial Locations (3)

Unknown

NOT_YET_RECRUITING

The Speciality Hospital, Amman

NOT_YET_RECRUITING

MNGHA- King Abdulaziz Hospital, Al Mubarraz

RECRUITING

Al Kuwait Hospital, Dubai

All Listed Sponsors
lead

Resverlogix Corp

INDUSTRY